Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Andra AP fonden

Andra AP fonden lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 583.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,912 shares of the biopharmaceutical company’s stock after purchasing an additional 24,680 shares during the period. Andra AP fonden’s holdings in Regeneron Pharmaceuticals were worth $18,028,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Orbimed Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $11,358,000. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $5,682,636,000. National Pension Service boosted its position in Regeneron Pharmaceuticals by 29.8% during the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock worth $278,636,000 after acquiring an additional 82,853 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $10,472,000. Finally, Contravisory Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at about $6,327,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.1%

Shares of REGN traded up $9.15 during mid-day trading on Tuesday, hitting $807.32. 244,562 shares of the company’s stock were exchanged, compared to its average volume of 829,892. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market cap of $83.12 billion, a price-to-earnings ratio of 19.98, a P/E/G ratio of 1.54 and a beta of 0.20. The stock’s 50-day moving average is $769.53 and its 200-day moving average is $720.46. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company posted $12.81 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on REGN shares. Wells Fargo & Company raised their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald boosted their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Fourteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $802.18.

Insider Buying and Selling

In other news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the sale, the executive vice president owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 4,146 shares of company stock valued at $3,432,488. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.